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cles. Then a set of tagging and extraction rules are applied to retrieve PK data from the article abstracts.
To estimate the PK parameter population-average mean and between-study variance, a linear mixed
meta-analysis model and an E–M algorithm are developed to describe the probability distributions of
PK parameters. Finally, a cross-validation procedure is developed to ascertain false-positive mining
results. Using this approach to mine midazolam (MDZ) PK data, an 88% precision rate and 92% recall rate
are achieved, with an F-score = 90%. It greatly out-performs a conventional data mining approach (sup-
port vector machine), which has an F-score of 68.1%. Further investigate on 7 more drugs reveals compa-
rable performances of our sequential mining approach.
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In recent decades, a newdrug requires an average of 15 years and
approaching a billion dollars in research and development. Unfortu-
nately, only one in 10 drugs that enter clinical testing receives even-
tual FDA approval [1]. Scientists have become increasingly
mechanistic in their approach to drug development [2]. The recent
ability to integrate geneticmutations and alteredprotein expression
to pharmacokinetics (PK) and pharmacodynamic (PD)models allow
a deeper understanding of themechanisms of disease and therapies
that are genuinely targeted [3–6]. In 2004, the FDA released a report
entitled: ‘‘Innovation or Stagnation, Challenge and Opportunity on
the Critical Path toNewMedical Products” [7]. Among its six general
topic areas, three of them emphasized the importance of computa-
tional modeling and bioinformatics in biomarker development and
streamlining clinical trials [8,9]. In multiple follow-up papers, clini-
cal researchers, experimental biologists, computational biologists,
and biostatisticians from both academia and industry all cheered
the FDA leadership in this critical path, and pointed out the chal-
lenges andopportunities of the PK/PDmodel based approach in drug
development [10–13].
To fulﬁll the PK/PD modeling potential in drug development,
there is an enormous need for pharmacology database of PK/PD
parameters. For example, to specify the ﬁrst human dose of all rights reserved.new compound, based on animal studies, one needs available in-vi-
tro and in-vivo PK parameters from its comparators (in market)
[10,13]. However, these PK data are rarely available from public
pharmacology databases. DiDB (http://www.druginteractioninfo.
org/) has manually accumulated published PK publications for
each drug. However, DiDB has no summarized PK parameters.
DrugBANK (http://redpoll.pharmacy.ualberta.ca/drugbank/) is a
comprehensive pharmacology database. It has collected rich anno-
tations on drug’s chemistry, structure, mechanism, pathway, and
targets, but has very sparse PK data. The other one is PharmGKB
(http://www.pharmgkb.org/). It stores enormous amount of phar-
macogenetics (PG) data from ongoing PG studies sponsored by
National Institute of General Medical Science (NIGMS), but very
limited PK data are available.
The shortage of manually maintained drug databases is the lack
of ability to ensure the completeness and timely update of PK
parameters. The widely used online literature search service, Pub-
Med, contains about 18 million abstracts from MEDLINE and addi-
tional life sciences journals. Its collection grows at 40,000 new
biomedical abstracts every month [14]. Even for some subsections
of the drug literature in PubMed, e.g. the drug therapy review
articles which grow about 10,000 English-language articles per
year [15]. Therefore, it is not possible to keep track of all relevant
literature manually. In addition, the complexity of information
from PK/PD studies makes it even harder for the data processing
when various drug doses, administration routes, patients, sample
collection intervals, and the like are involved into the collected
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collected depends heavily on the mechanistic of PK/PD models
and their simulations, which is in turn driven by the science. Thus
the required literature information becomes a moving target. Con-
sequently, the manual knowledge base accumulation approach
cannot meet all the challenges.
One effective alternative is literature mining [16,17], which
trains the machine to discover useful information or make novel
hypothesis on publications. Its machine learning methodology
has the advantage of processing large amount of information with-
in a short time, the ﬂexibility of adaptation and integration with
follow-up applications, e.g. PK/PD model developments. This tech-
nique has been applied on many biomedical research problems
[16], and has been proved sufﬁciently accurate to be used in prac-
tice [17]. However, there is no single strategy working equally well
for all types of information extraction requirements, and little re-
search has been done for the numerical pharmacokinetic data
extraction from scientiﬁc publications. This situation calls for the
development of a novel strategy speciﬁcally to extract the numer-
ical PK/PD parameters.
Literature mining on PK parameters is highly unique. Firstly,
important PK parameters (entities) are speciﬁcally deﬁned, e.g.
absorption rate, bioavailability, clearance, etc. These PK parameters
are usually available from different drug studies, which may vary
by factors such as units, sub-populations, study designs, and dose
regimens. Thus a set of experience based standards need to be cre-
ated to normalize the mined data. Secondly, the retrieved informa-
tion can be incomplete and unbalanced from different published
paper. So the missing information needs to be estimated and im-
puted from the known PK parameters according to their relation-
ships. Thirdly, false positive ﬁndings need to be cleaned from
mined results as thorough as possible.
One barrier in the study of literature mining is the relative lack
of standards to evaluate the performance of mining strategies. This
situation stimulates the generation of some ongoing evaluation re-
sources and benchmarks, e.g. Knowledge Discovery and Data Min-
ing (KDD) Challenge Cup [19], TREC Genomics Track [20],
BioCreAtIvE [21], etc. However, these evaluation resources are usu-
ally designed for other biomedical problems. As for the application
of numerical data targeted literature mining in the ﬁeld of PK/PD
study, little previous work is available for reference. Therefore,
one goal of our research is to establish a new validation data set
to offer to the community.
Additionally, in this paper, we test a novel literature mining
strategy we have developed. Our approach targets drug PK param-
eter numerical data extraction. It possesses entity recognition,
information extraction, and outlier detection. In particular, we em-
ploy a likelihood based statistical model to describe the distribu-
tion of PK parameters, develop an expectation-maximization
(EM) data evaluation algorithm to estimate the PK parameter pop-
ulation means and variances, and an outlier detection rule to re-
move false-positive mining results. The details of the mining and
evaluation methodology are presented in Section 2. The data min-
ing implementation for drug, midazolam (MDZ), is illustrated in
Section 3. Conclusions are reached in Section 4.
2. Methods
2.1. MDZ case-study overview
The goal of our literature mining approach is to extract all phar-
macokinetics (PK) related information for a given drug. In this pa-
per, we use midazolam (MDZ) as the test drug. The mining is based
on abstracts from PubMed. One example of a MDZ PK relevant ab-
stract is provided below [22].To study the effects of cirrhosis of the liver on the pharmacoki-
netics of midazolam single IV (7.5 mg as base) and p.o. (15.0 mg
as base) doses of midazolam were administered to seven
patients with cirrhosis of the liver and to seven healthy control
subjects. The elimination of midazolam was signiﬁcantly
retarded in the patients as indicated by its lower total clearance
(3.34 vs. 5.63 ml/min/kg), lower total elimination rate constant
(0.400 vs. 0.721 h1), and longer elimination half-life (7.36 vs.
3.80 h). The bioavailability of oral midazolam was signiﬁcantly
(P < 0.05) higher in patients than controls (76% vs. 38%).
The search engine of PubMed is not subtle enough to limit the
search results to a speciﬁc topic, i.e. human PK study. So a further
ﬁltering step is necessary to remove irrelevant articles from Pub-
Med search results, and keep the PK relevant abstracts which usu-
ally contain information from the following relevant keyterm
categories.
 Subject type (race, age, sex, etc.) and size.
 MDZ dose and administration route (oral, intravenous, etc.).
 PK parameters, such as AUC (area under the concentration–time
curve), half-life, bioavailability, clearance, etc.
Besides the keyterm categories above, we limit the mining to PK
data from healthy human subjects and the target drug only (i.e. no
other factors involved such as drug inhibitor/activator) to comply
with the requirements of drug PK study.
Hence, in the example abstract, the literature mining tool
should be able to extract ‘‘seven healthy control subjects” as sub-
ject, ‘‘IV (7.5 mg as base) and p.o. (15.0 mg as base)” as dose,
‘‘3.34 vs. 5.63 ml/min/kg” as total clearance, ‘‘0.400 vs. 0.721 h1”
as elimination rate, ‘‘7.36 vs. 3.80 h” as half-life, and ‘‘76% vs.
38%” as bioavailability. To be more precise, the mining tool should
be able to recognize which value is for drug MDZ in the comparison
situation, e.g. for the total clearance data, ‘‘3.34 ml/min/kg” is from
patients and ‘‘5.63 ml/min/kg” is from healthy subjects.
To achieve the goal above, we developed a rule-based infor-
mation extraction system. The architecture is shown in Fig. 1.
The abstracts are downloaded from PubMed after an initial
query for a target drug, e.g. midazolam. Abstract texts are pre-
processed such that they are divided into sentences, and differ-
ent forms of the same terms are trimmed. The next step is
entity recognition. It determines sentence relevance, and tags
the trimmed sentence terms as various entity classes. At the
end of this step, only the more relevant abstracts are left and
well tagged. In the information extraction step, a set of extrac-
tion rules are manually created and implemented. Then the
mined data are analyzed by a statistical model to detect and re-
move outliers, which are potential false positive data. The ﬁnal
data set is saved into a PK parameter database.Fig. 1. The architecture of literature mining tool.
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Our PubMed search uses the drug name, e.g. midazolam, as the
unique keyterm in a query. The search results are downloaded
with the XML format to get the structured abstract information.
In the following mining process, only article title (hArticleTitlei),
abstract (hAbstractTexti) and paper type (hPublicationTypei) infor-
mation is utilized from the XML format abstract.
The goal of the preprocessing step is to split the abstract text
into units of sentences. There are some existing tools to do this
job (e.g. SentenceDetector [23], MxTerminator [24]). Considering
the simple grammar of the abstracts, we applied a Perl module
(Lingua::EN::Sentence) for sentence splitting. The Porter stemming
algorithm [25] is used to deal with the commonmorphological and
inﬂexional endings from words in English. After stemming, each
word in the abstracts is normalized into a standard form.
2.3. Entity recognition
2.3.1. Entity template library
Keyterm based PubMed search usually returns a large number of
abstracts, e.g. 7129midazolamabstracts. To increase theprecisionof
themined results, an abstract ﬁltering step is necessary after the text
preprocessing. Firstly, aswe limit theminingof PKdata fromhealthy
human subjects, the studies on diseased subjects should be re-
moved. The human subject information (health status, race, weight,
etc.) is highly important and usually reported in pharmacokinetics
studies. Most article abstracts state clearly whether the human sub-
jects are healthy or diseased (patients). So if one abstract only men-
tions patients or diseased subjects, it is usually irrelevant; but if
there is co-existence of healthy subject information (this is usually
the control in clinical studies), it is still considered as subject rele-
vant. For abstracts without any subject information, we kept them
as relevant in case of data loss. Secondly, an entity template library
is built based on expert knowledge for the further abstract ﬁltering.
It summarizeskey factors indetermininganabstract’s relevance. Ta-
ble 1 is a library example, which contains a list of relevant keyterms
and a list of forbidden terms. The terms are in the stemmed format.
Because some relevant abstracts do not have human subject infor-
mation, subject terms are not included in the keyterm list. Thus,
these articles can be kept as relevant for future full text mining pur-
poses. In addition, the drug related terms should correspond to the
studied drug. For midazolam, such terms are ‘‘midazolam”, ‘‘mdz”,
‘‘cyp3a”, and ‘‘p450”.Table 1
Keyterms and forbidden terms.
Keyterms Forbidden terms
ROUTE orally NTITLE mice
intraven mouse
administr rat
i.v. animal
intramuscular penguins
DRUG hDrug termsi pig
horse
human liver
microsom
review
PK clearance NTYPE review
pharmacokinet
concentr
bioavail
auc
elimin
c(max)
half-lifThe entity template library is a representation model for the rel-
evant abstracts. The PubMed search abstracts are further ﬁltered
by this library. An abstract is considered relevant if it contains at
least one term from each of the keyterm categories, which include
drug administration routes (ROUTE), PK parameters and DRUG (Ta-
ble 1); and the abstract is considered as irrelevant if it contains one
or more forbidden terms in either hNTITLEi or hNTYPEi (Table 1). As
MDZ is primarily a CYP3A substrate, all of its DRUG keyterms are
related to this metabolic enzyme. The hNTITLEi is the forbidden
term list for article titles. These terms mostly represent animal
and in-vitro studies (Table 1). The other forbidden term, hNTYPEi,
is used to recognize the review articles. Since review articles con-
tain PK data only from other publications, they do not provide
additional information.
2.3.2. Tagging entities
All information in the keyterm categories is necessary for a drug
PK study. In order to extract all the PK data from the abstract, it is
critical to properly tag all these relevant terms in each sentence.
2.3.3. Subject tagging
The subject information usually contains all or part of the fol-
lowing four key components: size, description, race and subject
types (Table 2). hSUB_part: termi is used to represent a term in
each component, e.g. ‘‘seven healthy control subjects” can be
tagged as ‘‘hSUB_N: seveni hSUB_D: healthyi control hSUB_T: sub-
jectsi”. The subject tagging starts from searching the TYPE compo-
nent in one sentence, then trace back to the other components. If at
least two components exist in one sentence, they are tagged as
subject information.
2.3.4. Drug tagging
Most PK study related abstracts cover multiple drug names, e.g.
drug–drug interaction studies. PK parameters in these abstracts are
available for multiple drugs. The mining tool should recognize dif-
ferent drug names. A complete list of all the approved drugs from
the U.S. Food and Drug Administration (FDA) website is down-
loaded, and a drug name dictionary is built from this list. Thus,
the drug entities in the abstracts can be correctly tagged, e.g.
midazolam to hDRUG: midazolami.
2.3.5. Dosing tagging
The dosing tagging information is illustrated in Table 3. The ﬁrst
column shows different drug administration ways, and the second
column lists all possible units for dosing. The dose is located by
searching the numerical data lying ahead of its unit. In sen-
tences, the administration routes and units after numerical data
are important dosing tags. As these tags are highly compact,
they usually occur together. For example, the following two dosing
related text segments
 Midazolam oral (15 mg) and intravenous (0.05 mg kg1) was
givenTable 2
Subject related terms.
Number (N) Description (D) Race (R) Type (T)
[0–9] Young Chinese Volunteers
{one. . .ten} Healthy Japanese Subjects
{eleven. . . twenty} Medication-free Vietnamese Individuals
Elderly European Women
{thirty. . . ninety} Male Caucasian Men
Female Mexican Americans
White American Immigrants
Premenopausal African
Nonsmoking
Table 3
Dosing information.
Administration (A) Unit (U)
Oral/orally mg
iv/i.v. mg
po/p.o. lg
s.c. mg kg(1)
Infuse mg(1) kg
Intramuscular mg/kg
Intravenous/intravenously mg kg1
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are tagged as
 hDRUG: Midazolami hDose_A: orali (15 hDose_U: mgi) and
hDose_A: intravenousi (0.05 hDose_U: mg kg1i) was given
 7.5 hDose_U: mgi dose of hDRUG: Midazolami was given
hDose_A: orallyi.2.3.6. PK parameter tagging
Drug clearance is chosen as the test PK parameter data mining
performance, since it has comparably more numerical data avail-
able in the abstracts. The important tags for the clearance relevant
value and unit are,
 Clearance terms (T): [systemic/oral] clearance.
 Value (V).
 Unit (U) examples: ml/min/kg; l/kg/h; ml/min; l/h.
As there are two types of clearance, systemic clearance and oral
clearance, a type classiﬁcation is needed in the following data anal-
ysis step. The clearance value is usually reported in both sample
mean and standard deviation. The co-existence of the clearance
keyterms and units is a unique identiﬁcation, and the tagging is
done by identifying them together in one sentence. For example,
the phrase ‘‘the systemic clearance of midazolam was unchanged
(37.7 ± 11.3 l/h)” is tagged as ‘‘the hCLR_T: systemic clearancei of
hDRUG: midazolami was unchanged (hCLR_V: 37.7 ± 11.3i hCLR_U:
l/hi)”.
After the tagging process, the relevant elements in each sen-
tence are recognized. The tagged sentences in each abstract are
kept for the following information extraction. All the untagged sen-
tences are removed.
2.4. Information extraction
Information extraction is to extract the information from three
prescribed tagging items: dosing, subject, and PK parameters. The
subject and dosing information can be extracted easily given a well
tagged sentence. For example, given the tagged phrase ‘‘hSUB_N:
seveni hSUB_D: healthyi control hSUB_T: subjectsi”, themachine eas-
ily locates the subject information. Similarly, the tagged phrase ‘‘7.5
hDose_U: mgi dose of hDRUG: Midazolami was given hDose_A:
orallyi” clearly shows ‘‘7.5 mg orally” as the dosing information for
midazolam.The tagged sentence ‘‘hDRUG:Midazolami hDose_A: orali
15 hDose_U:mgiand hDose_A: intravenousi0.05 hDose_U:mg kg1i ‘‘
indicates a simple sequential parsing of information for oral dosing
and intravenous dosing as ‘‘oral 15 mg; intravenous 0.05 mg kg1”.
PK parameter data extraction is more complicated. As multiple
drugs are usually involved into the PK studies, one abstract sen-
tence may contain PK data for both target drug and other drugs.
Even if one sentence discusses the target drug only, the data can
reﬂect its PK value change caused by other study drugs. The follow-
ing sentence reﬂects this complexity.
Rifampin signiﬁcantly (P < 0.0001) increased the systemic and
oral clearance of midazolam from 0.44 ± 0.2 L h/kg and1.56 ± 0.8 L h/kg to 0.96 ± 0.3 L h/kg and 34.4 ± 21.2 L h/kg,
respectively.
Two drugs, midazolam and rifampin, are mentioned in this
sentence, and the clearance values contain both control and af-
fected cases. The information extraction needs to make the cor-
rect decision that this sentence discusses midazolam, but not
rifampin; and the control clearance values come ﬁrst (0.44 ± 0.2
for systemic clearance; 1.56 ± 0.8 for oral clearance). There are
two steps to discriminate the target drug. First, if the title or
the occurrence frequency of term ‘‘midazolam” shows strong sig-
nal that the abstract is about midazolam but not rifampin, this
sentence is most likely to be midazolam. Secondly, it is still pos-
sible that one clearance value is for rifampin for the sake of com-
parison. In order to deal with this case, a set of extraction rules
are created. The rules are explained in detail in the follow up
example. After the tagging step, this sentence example is con-
verted to
hDRUG: Rifampini signiﬁcantly (P < 0.0001) hCHG: increasedi
the hCLR_T: systemici and hCLR_T: oral clearancei of hDRUG:
midazolami from hCLR_V: 0.44 ± 0.2i hCLR_U: L. h/kgi and
hCLR_V: 1.56 ± 0.8i hCLR_U: L h/kgi to hCLR_V: 0.96 ± 0.3i
hCLR_U: L h/kgi and hCLR_V: 34.4 ± 21.2i hCLR_U: L h/kgi,
respectively.
The tag ‘‘hCHGi” is an important one to show the change of
clearance value caused by the co-existence of other drugs. Hence,
the ‘‘increased” case of hCHGi tag, the smaller value of clearance
data is usually the control, i.e. study with no drug interaction ef-
fect, which should be extracted. Now the simple representation
pattern for this sample sentence is ‘‘hDRUG1i hCHGi hCLR_T1i
hCLR_T2i hDRUGi hCLR_V1i hCLR_V2i hCLR_V3i hCLR_V4i”. The
rules to extract clearance information for this type of pattern are
listed below:
 Find clearance type hCLR_T1i hCLR_T2i.
 Find value change type hCHGi.
 Each value change involves two clearance values for one clear-
ance type, hence there should be four clearance values
(hCLR_T1_V1i to hCLR_V4i).
 The clearance values for hCLR_T1i can be (hCLR_V1i hCLR_V2i) or
(hCLR_V1i hCLR_V3i). Choose the pair with the smaller differ-
ence, and the smaller value in that pair is hCLR_T1i. For example,
the systemic clearance is 0.44 ± 0.2 L h/kg.
 The other two values are for hCLR_T2i. Similarly, the smaller
value of the two is chosen for hCLR_T2i. For example, the oral
clearance is 1.56 ± 0.8 L h/kg.
These extraction rules cover regular expressions of clearance
data, considering single and multiple drug occurrences, different
clearance types, and clearance value changes.
2.5. Evaluation – linear mixed model meta-analysis for PK parameter
estimation and outlier detections
Because the mined PK parameter numerical data may contain
some false positive values, an evaluation mechanism is needed to
remove them as outliers. The population mean and variance of
PK parameters are also requested to be estimated. We developed
a linear mixed model meta-analysis approach for this purpose.
The PK parameter values are assumed to follow the normal distri-
bution as illustrated in Eq. (1).hk  Nðhk; se2kÞ hk  Nðh;r2Þ ð1Þ
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(the sample mean of study k) has study-speciﬁc mean hk, sample
standard error se2k , where k = 1, . . . , K, indicates the studies. The
second normal distribution is at the population level, in which hk
has the population mean h, and r2 is its between-study variance.
The population and study level PK parameters are two common
statistics concepts in the pharmacokinetics meta-analysis litera-
ture [28]. The population PK parameter refers to its population-
average mean, and a study-speciﬁc PK parameter refers to its
sub-population mean, in which the study was sampled from. In
this paper, we assume that PK data from one paper is a study,
which is denoted by k.
In Eq. (1), hk and se2k are observed data from the literature
mining results. The unknown parameters h, r2 and hk are estimated
by the following expectation and maximization algorithm. The
expectation step estimates hk by Eq. (2).
h^k ¼ 1se2k
þ 1
r2
 1

hk
se2k
þ h
r2
 
ð2Þ
The values of population mean h and population variance r2 are
estimated in the maximization step by Eq. (3). The E–M iterative
procedure stops when the estimated values are stable.
Lðh;r2; hkjhk; se2kÞ /
Y
k
Nðhk; se2kÞ  Nðh;r2Þ
@
@h
log L ¼ 0 ) h^ ¼
Pn
k¼1hk
n
@
@r2
log L ¼ 0 ) r^2 ¼
Pn
k¼1ðhk  hÞ2
n
ð3Þ
Based on the meta-analysis, the standard error of the estimated
population mean is expressed in Eq. (4),
seðhÞ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1PK
k¼1
1
ðr2þse2
k
Þ
vuut : ð4Þ2.6. Validation and classiﬁcation
Some PK parameters have multiple types, but the abstracts do
not always state clearly which type a numerical data refers to,
e.g. some MDZ abstracts just use a single word ‘‘clearance” to rep-
resent either systemic clearance or oral clearance. In order to clas-
sify the unknown clearance type, the probability functions are
established from known oral and intravenous clearance data withFig. 2. Precision performance analysis of the machineprescribed linear mixed model. Denote them as, P½jhPO; se2PO;r2PO
and P½jhsys; se2sys;r2sys, respectively. For an unknown type sample
mean clearance value, hk;unknown is classiﬁed by Eq. (5).
P½hk;unknownjhPO;se2PO;r2PO> P½hk;unknownjhsys;se2sys;r2sys) type¼ PO;
P½hk;unknownjhPO;se2PO;r2PO< P½hk;unknownjhsys;se2sys;r2sys) type¼ Systemic:
(
ð5Þ
Then a leave-one-out strategy is implemented to validate the
classiﬁcation results. For each classiﬁed data set, one single data
is taken out and the rest go through the prescribed linear mixed
model meta-analysis (Section 2.5). If this left-out data is 2.5 stan-
dard deviations from the population mean, it is considered as an
outlier. To save the computation time, the data are ranked ﬁrst,
and this leave-one-out process is conducted iteratively from both
the bottom and the top of the ranked data until the left-out data
is not considered as outliers.3. Results
3.1. MDZ data mining
3.1.1. Entity recognition
In this paper, midazolam (MDZ) is used to test our literature
mining strategy. The keyterm ‘‘midazolam” in PubMed search re-
turns over 7129 article records. After applying the entity template,
out of the 7129 PubMed abstracts, 393 abstracts are considered as
MDZ PK relevant. Among those 393 abstracts, 170 are truly rele-
vant by the manual checking. The precision is 43%.
3.1.2. Information extraction
From 393 abstracts, the information extraction returns 53 ab-
stracts. 43 out of 53 abstracts contain the true MDZ clearance data.
Hence the precision improves to 81%. The same information
extraction rules are also applied directly to the starting 7129 Pub-
Med abstracts. It returns 120 abstracts, and a much lower preci-
sion, 36% (dashed lines in Fig. 2). This analysis shows the
importance and the power of the entity template step.
3.1.3. Evaluation
Linear mixed model meta-analysis is implemented to classify
the oral and systemic clearances, and remove the outlier data
and abstracts. After this evaluation step, only 48 ﬁnal abstracts
are left, and 42 of them are true (precision 88%). The precision oflearning algorithm in all MDZ related abstracts.
Table 4
Mined and Validated MDZ Clearance Data.
Oral Systemic Unknown
Mined Clearance
data (L/h)
0.72, 4.9, 8.2, 31.98,
42.6, 43.2, 52.32,
68.64, 84.78, 109.2,
116.8, 124.8,
137, 152, 215.9, 1289
15.12, 18.6, 22.98, 28,
32, 33.06, 33.6, 35.2, 36.9,
37.7, 77.28, 84.78
0.81, 1.14, 2.016, 2.11, 2.26, 2.4, 3, 4.6, 5.58, 6.6, 14.94, 15.9, 16.75, 16.98, 19.02, 19.38, 19.5, 20.16,
21.12, 21.5, 22.2, 22.56, 23.28, 23.3, 23.4, 23.5, 23.52, 23.664, 23.94, 24, 24.8, 25.14, 25.2, 25.86, 25.92,
27.024, 27.78, 28, 28.2, 28.8, 28.96, 29.904, 30.12, 30.64, 32.16, 33.78, 34.08, 36.77, 36.96, 37.44,
37.92, 38.88, 39.17, 39.22, 40.8, 42.4, 45.12, 45.6, 46.08, 51.2, 52.8, 53.8, 54.6, 54.72, 58.56, 59.04, 59.2,
66.24, 78.6, 97.5, 99.36, 132, 144, 146, 166.56, 1281, 2272, 3328, 5472, 17616
Oral Systemic
Clearance after
evaluation (L/
h)
42.4, 42.6, 43.2, 45.12, 45.6,
46.08, 51.2, 52.8, 53.8, 54.6,
54.72, 58.56, 59.04, 59.2, 66.24,
68.64, 78.6, 97.5, 99.36, 109.2,
116.8, 124.8, 132, 137, 144,
146, 152, 166.56
14.94, 15.12, 15.9, 16.75, 16.98, 18.6, 19.02, 19.38, 19.5, 20.16, 21.12, 21.5, 22.2, 22.56, 22.98, 23.28,
23.3, 23.4, 23.5, 23.52, 23.664, 23.94, 24, 24.8, 25.14, 25.2, 25.86, 25.92, 27.024, 27.78, 28, 28, 28.2,
28.8, 28.96, 29.904, 30.12, 30.64, 32, 32.16, 33.06, 33.6, 33.78, 34.08, 35.2, 36.77, 36.9, 36.96, 37.44,
37.7, 37.92, 38.88, 39.17, 39.22, 40.8, 42.4, 45.12, 45.6, 46.08, 51.2
Note: The mined clearance data have three types: oral, systemic and unknown type. The false positive data was labeled italics; the false negative data which was removed in
the validation step was labeled bold.
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data extraction, and reaches 88% after evaluation.
3.1.4. MDZ clearance parameter estimation and outlier detections
The MDZ PK clearance data from the information extraction are
shown in the ﬁrst row of Table 4. The mined clearance data have
three types: oral clearance, systemic clearance and clearance with
unknown mechanisms. The values are normalized based on an
estimated average human body weight 80 kg, and veriﬁed by man-
ually going through the abstracts. False positive clearance data are
labeled in italics.
The mined clearance data then go through the linear mixed
model meta-analysis to estimate the distributions for the sys-
temic/oral clearance and remove the outliers. The calculated distri-
butions are displayed in Fig. 3. The population mean ± se of
systemic clearance is 27.8 ± 1.0 L/h, and its between-study stan-
dard deviation is 7.31; oral clearance is 78.1 ± 6.0 L/h, and its be-
tween-study standard deviation is 32.8.Fig. 3. The estimated clearance distribution. Note: The blue curve shows systemic
clearance; the green curve shows oral clearance. The 95% conﬁdence interval is
marked on each curve using vertical lines. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of this article.)Based on the distributions, the unknown type of clearance data
were classiﬁed into oral clearance or systemic clearance, and out-
liers were removed. After the evaluation process, the ﬁnal mined
MDZ clearance data was shown in the second row of Table 4. The
evaluation removes most of the false positive data. The left false
positive data are comparable to the true clearance data, and they
cannot be identiﬁed as outliers. Some true MDZ clearance data, la-
beled bold in the ﬁrst row of Table 4, are considered as outliers by
the evaluation. The clearance data before and after the evaluation
are shown in Fig. 4. Obviously the meta-analysis can efﬁciently
classify the data and remove the outliers.
3.1.5. Performance comparisons with DiDB database
To better evaluate our literature mining method, we compare
the extracted MDZ clearance data with those from DiDB database.
DiDB [26] is the most complete PK database so far, which is built
manually. DiDB MDZ clearance data are downloaded and are com-
pared with the mining MDZ clearance data. Table 5 lists detailed
comparisons. DiDB [26] provides 11 PK relevant articles for MDZ.
We read through their abstracts and ﬁnd only six clearance data
from healthy subjects. While the mining returns 170 PK relevant
articles for MDZ, in which more than 70 clearance data are ex-
tracted from the abstracts. Therefore, the literature mining method
possesses 70/6 = 11.6 times fold increase in information content, in
addition to the beneﬁts of the automatic data extraction.
The population mean and its standard error ðh seÞ are calcu-
lated for DiDB clearance data and the mined clearance data. The
true known population mean and standard error, which are calcu-
lated based on the manually extracted clearance data from rele-
vant article abstracts, are given as a comparison benchmark. For
the oral clearance, the benchmarker estimate is 83.6 ± 8.6 (L/h),
while the DiDB and mining estimates are 58.3 ± 16.8 and
78.1 ± 6.0, respectively. Comparing to the benchmarker, the DiDB
estimate is much more biased than our mining approach, 30.3%
vs. 6.6%; and DiDB estimate’s se is 2.8 times higher than our mining
approach. For the systemic clearance, comparing to the bench-
mark, DiDB estimate’s bias = (32.3–25.8)/32.3  100% = 20.1%, and
mining estimate has a bias of 13.9%. DiDB estimate’s se is 3.1 times
higher than the se of our mining estimate.
One observation on the DiDB oral clearance data is the inﬂuence
of the publication errors on thedata analysis. PubMedPID15470333
reported oral clearance for midazolam as 533 ± 759 ml/min by typo
in theabstract. The correct value shouldbe1533 ± 759 ml/min in the
full text. In the meta-analysis of our text mining, the inﬂuence of
such error is eliminated by the outlier detection. However, DiDB
database suffers from this type of publication error, and we suspect
that DiDB only reads the abstract sometimes.
Fig. 4. MDZ clearance data. (a) Contains all mined MDZ clearance data before evaluation and outlier removal, and (b) contains the MDZ clearance data after evaluation outlier
removal. The blue dots are true clearance data from MDZ PK relevant abstracts; the red and green dots are false MDZ clearance data, in which the red ones were removed by
EM validation as outliers and green ones were not. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 5
MDZ clearance estimate comparisons among true known data, DiDB, and mining results.
True known DiDB Mining
Abstract PK
#
Relevant article
#
h ± se Abstract PK
#
Relevant
article #
h ± se Abstract PK
#
Relevant article
#
h ± se
Oral clearance 25 170 83.6 ± 8.6 2 11 58.3 ± 16.8 (88.4 ± 7.3)a28 170 78.1 ± 6.0
Systemic
clearance
50 32.3 ± 1.8 4 25.8 ± 3.1 59 27.8 ± 1.0
Note: This table shows how many PK relevant articles (‘‘relevant article #”) were are available, and how many clearance data (‘‘abstract PK #”) were extracted from their
abstracts.
a The estimate of oral clearance after an outlier (publication bias in DiDB) is removed from the data set. This outlier is automatically removed in our mining approach.
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3.2.1. Validation data generation
The classical way to evaluate the performance of information
retrieval is to check its recall and precision. In this case study,
the quality of the entity template determines how well the MDZ
PK relevant abstracts can be retrieved. However since the sample
data (over 7000 abstracts) from PubMed search are too big to be
handled manually for the recall and precision analyses, a subset
of the abstracts are generated to estimate the performance of each
literature mining step.
To build such a subset, one more keyterm ‘‘pharmacokinetics” is
included into thePubMedsearch. Thisdecreases the sizeof the result
abstracts to 819, a reasonable number for the manual performance
check. The results are shown in Fig. 5. The manual inspection of
the 819 abstracts returns 164 PK relevant articles for drug MDZ.3.2.2. Entity recognition
After applying the entity template, 220 out of the 819 ab-
stracts are left in which 150 abstracts are truly relevant. The re-
call of this information retrieval step is 91% and the precision is
68% (Table 6).
3.2.3. Comparison with automatic abstract classiﬁcation
To evaluate the power of this entity template, we compare
the performance of template based abstract classiﬁcation with
an automatic classiﬁer implemented using a support vector ma-
chine (SVM). Training data were established by dividing the 164
relevant abstracts into three groups with about 55 abstracts in
each, then adding to each group 55 randomly selected irrelevant
abstracts. The group which generates higher F-score was
recorded as SVM (50). We applied a two-step process to deter-
mine proper features for SVM. First, a chi-square based feature
Fig. 5. Recall and precision performance analysis of the machine learning algorithm in a MDZ abstracts subset.
Table 6
Comparison between template and SVM methods on MDZ abstract relevance.
Method Total Query TP FP FN TN Precision (%) Recall F-score Accuracy
MDZ-relevance
PubMed Query NA 819 164 655 NA NA 20.0 NA NA NA
PubMed query + entity template 819 220 150 70 14 585 68.2 91.5% 78.1% 89.7%
SVM (50) 819 159 110 49 54 496 69.2 67.1% 68.1% 74.0%
SVM (100) 819 277 142 135 22 520 51.3 86.6% 64.4% 80.8%
Note: The training data of SVM (50) contains 50 randomly selected relevant abstracts and 50 irrelevant; the training data of SVM (100) contains 100 randomly selected
relevant and 100 irrelevant. (TP, FP, FN, and TN) stand for true positive, false positive, true negative, and false negative, respectively.
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below threshold 0.05. Then, the remaining features went through
a principle component analysis [27] for dimensionality reduction,
which was set to keep a cumulative proportion 95% of the origi-
nal features. The ﬁnal features were fed into SVM for model
training and classiﬁcation. We also tried a second training data
set, which was made up of 100 randomly selected abstracts from
the 164 relevant articles and 100 randomly selected irrelevant
abstracts. The SVMlight [18] was implemented with different ker-
nels, and the best performance was shown in Table 6. The pre-
cision/recall is measured on information retrieval, ﬁnding
relevant articles out of the test set of abstracts. SVM (50) has
slightly higher precision than our entity template in identifying
MDZ relevant abstracts (69.2% vs. 68.2%), but much worse recall
(67.1% vs. 91.5%). Hence SVM (50)’s F-score is lower than entity
template (68.1% vs. 78.1%). On the other hand, SVM (100) gener-
ates reduced precision, 51.3%, and improved recall, 86.6%. Its F-
score becomes even worse, 64.4%. Overall, our literature mining
approach out-performs SVM. As the features used for SVM (100)Table 7
clearance extraction with and without entity template.
Method Total Query
Clearance-relevance
PubMed query + CL extraction 819 103
PubMed query + entity template + CL extraction 819 45
PubMed query + CL extraction + outlier evaluation 819 73
PubMed query + entity template + CL extraction + outlier evaluation 819 41covers only 56% of the template features, to further explore the
difference between the template based classiﬁcation with SVM,
we combined the features from the chi-square feature selection
with template features and fed them directly into SVM for model
training and classiﬁcation. The inclusion of extra features did not
improve the performance of SVM at all. It is possible that SVM
has not been able to model many non-linear or interactive rela-
tionships, which were introduced into the templates implicitly.
3.2.4. Information extraction
For the clearance data, the manual inspection proves 39 out of
the 164 relevant abstracts containing MDZ clearance numerical
values (clearance relevant). Our information extraction step recog-
nizes 45 abstracts as clearance relevant, in which 37 are true.
Hence, the recall rate for clearance data extraction is 95% and the
precision is 82%. The same information extraction rules are also ap-
plied directly to the starting 819 abstracts (Table 7). Without the
application of entity template, the precision drops from 82% to
38%, and F-score reduces from 88% to 55%.TP FP FN TN Precision (%) Recall (%) F-score (%) Accuracy (%)
39 64 0 716 37.9 100.0 54.9 92.2
37 8 2 772 82.2 94.9 88.1 98.8
39 34 0 746 53.4 100.0 69.6 95.8
36 5 3 775 87.8 92.3 90.0 99.0
Table 8
CL data extraction on more drugs: DiDB vs. literature mining.
Drug name DiDB Mining Comparisons
N n p (%) N n p (%) Coverage n-FC p-FC
Information content comparison
Triazolam 37 6 16 11 11 100 100% 1.83 6.25
Alprazolam 44 8 18 22 18 82 100% 2.25 4.55
Nifedipine 41 5 12 22 11 50 100% 2.2 4.12
Nitrendipine 2 0 0 5 3 60 N/A Inf Inf
Diazepam 3 3 100 4 3 75 100% 0 0.25
Amlodipine 4 1 25 5 4 80 100% 4.0 3.2
Nitrendipine 2 2 100 5 3 60 100% 1.5 0.40
Note: N, total number of reported abstracts in DiDB; and number of extracted
abstracts from text mining.
n, clearance relevant abstracts.
p, precision = n/N.
Coverage, the percentage of DiDB clearance relevant abstract covered by text
mining approach.
n-FC, fold-change from DiDB to mining in clearance relevant abstracts, n.
p-FC, fold-change from DiDB to mining in precision, p.
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The meta-analysis evaluation removed most outliers and false
positive values. After this step, the clearance data from 41 abstracts
are left and 36 of the abstracts are true MDZ clearance relevant.
The recall rate becomes 92% and the precision is improved to
88%. Similarly, without the entity template step, both the F-score
and precision drop signiﬁcantly (Table 7), from (90%, 88%) to
(70%, 53%).
3.2.6. Comparison of MDZ data mining and its validation analysis
Figs. 2 and 5 show the PK information comparison between sin-
gle PubMed search keyterm (‘‘midazolam”) and two keyterms
(‘‘midazolam” and ‘‘pharmacokinetics”). Though the PubMed
search returns much more abstracts using a single keyterm than
using two keyterms (7129 vs. 819), only six more relevant ab-
stracts are found in the single term search results (170 vs. 164).
The difference of the number of clearance relevant abstracts is also
six (45 vs. 39).
3.3. Information content comparison with DiDB
Table 5 suggests that our literature mining approach collects 11
times more MDZ clearance data than the manually curated DiDB
database contains. To test the portability of our literature mining
method, we tried it on 7 other Cytochrome P450 3A Subfamily
drugs and extracted their clearance data from PubMed abstracts
as for Midazolam. The same drugs were also searched in DiDB
database (September 2008), and clearance data was also analyzed.
The comparison was shown in Table 8. Among 5 out of 7 drugs,
comparing to DiDB, literature mining generates 1.83- to 4.0-fold
more information contents in CL, and precision increases from
3.2 to inﬁnite fold higher. Among those two drugs that DiDB out-
performs literature mining, our approach only misses totally two
abstracts.4. Conclusions
In this paper, we tested the feasibility of literature mining on
drug PK parameter numerical data by designing a sequential min-
ing strategy. Firstly, an entity template library is built to retrieve
pharmacokinetics relevant articles. Then a set of tagging and
extraction rules are applied to retrieve PK data from the article ab-
stracts. To estimate the PK parameter population mean and be-
tween-study variance, a linear mixed meta-analysis model andan E–M algorithm are established to describe the distribution of
PK parameters. Finally, a leave-one-out cross-validation procedure
is developed to ascertain false-positive mining results based on the
linear mixed meta-analysis model. Using this approach to mine
MDZ PK data, an 88% precision rate and 92% recall rate are achieved.
A conventional data mining approach, SVM, is compared to our
method. Its performance is nowhere near our approaches. Our text
mining approach recollects 11 timesmore MDZ clearance data than
a manual accumulated DiDB database has. Interestingly, it also
identiﬁes a publication error of midazolam clearance data, which
cannot be assessed in the DiDB database. In addition, we also
establish the ﬁrst validation set for more general data mining
methodology development for PK data.
With extensive evaluation, it reveals that our literature mining’s
outstanding recall and precision performance is largely due to the
well constructed entity template. This entity template out-
performs SVM in identifying MDZ relevant abstracts. We further
investigate our literature mining approach in 7 more CYP3A sub-
strate drugs. Among ﬁve out of seven drugs, comparing to DiDB, lit-
erature mining generates 1.83- to 4.0-fold more information
contents in CL, and precision increases from 3.2 to inﬁnite fold
higher. Among those two drugs that DiDB out-performs literature
mining, our approach only misses totally two abstracts. Therefore,
from the information content point of view, our data mining ap-
proach out-performs DiDB. At the meantime, since we imple-
mented statistical model based evaluation strategies for the
mining data, our integrated approach can identify outliers for qual-
ity control (QC). As a side production of QC, we provide not only
population PK parameter estimates of PK parameters, but also their
variations estimates. These features are not available in DiDB. Most
importantly, DiDB could have update lag, while our approach is in
real time.
The performance of our proposed mining strategy on MDZ PK
study is so promising that this feasibility study encourages us for
more case studies. Although the entity recognition template is very
general in our current setting, its performance on the other drugs
needs more assessment. Please note that MDZ usually serves as a
CYP3A probe drug in pharmacokinetics studies, its information is
in general richer than the other non-probe drugs.
For the mining of pharmacokinetics data, one important issue is
the drug name recognition. In this study, the co-existence of other
drugs was tagged for syntax analysis in the information extraction
step. Furthermore, their interactions with the object drug can be
considered to provide extra information for the mining. For exam-
ple, inducers (e.g. rifampin) of midazolam increase its clearance
and inhibitors decrease it. This brings in a valuable guidance for
clearance data extraction if the inducer/inhibitor of the object drug
can be tagged correctly. In this paper, we built a drug name dictio-
nary based on FDA databases. We are also evaluating other re-
sources for more drug information, e.g. DrugBank (http://
www.drugbank.ca), PubChem (http://pubchem.ncbi.nlm.nih.gov),
Drugs.com and RxList (http://www.rxlist.com).
The research presented in this paper also inspires our next step
work on the application of the literature mining technique, which
is full text based mining on drug PK data. As full texts usually con-
tain much more PK numerical data than abstracts, we should be
able to get more useful information. For example, the deﬁnition
of ‘‘population PK parameter” in the data evaluation step is only
under the statistical consideration. Whether the population repre-
sents the ‘‘world population” is highly debatable. In principle, it
should be determined by the racial, gender, and study location
compositions from different studies. This annotation information
is not always available in the abstracts, but is available in the full
text. Thus the full text articles would be the actual resource for
building the drug PK database. The current work in this paper
serves a very much needed starting point.
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